NASDAQ:BLUE bluebird bio (BLUE) Stock Price, News & Analysis $0.92 +0.01 (+1.09%) (As of 07/5/2024 ET) Add Compare Share Share Today's Range$0.90▼$0.9350-Day Range$0.85▼$1.1252-Week Range$0.85▼$5.53Volume3.08 million shsAverage Volume5.85 million shsMarket Capitalization$100.95 millionP/E RatioN/ADividend YieldN/APrice Target$5.46 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get bluebird bio alerts: Email Address bluebird bio MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside491.6% Upside$5.46 Price TargetShort InterestBearish26.96% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.76) to ($1.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.24 out of 5 starsMedical Sector703rd out of 879 stocksBiological Products, Except Diagnostic Industry116th out of 149 stocks 3.1 Analyst's Opinion Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 3 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst Coveragebluebird bio has received no research coverage in the past 90 days.Read more about bluebird bio's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted26.96% of the outstanding shares of bluebird bio have been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in bluebird bio has recently increased by 1.24%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLUE. Previous Next 1.4 News and Social Media Coverage News Sentimentbluebird bio has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for bluebird bio this week, compared to 6 articles on an average week.Search InterestOnly 19 people have searched for BLUE on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about bluebird bio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for bluebird bio are expected to grow in the coming year, from ($1.76) to ($1.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about bluebird bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Digital Mavericks Media1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.Click here to check it out. About bluebird bio Stock (NASDAQ:BLUE)bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Read More BLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLUE Stock News HeadlinesJuly 3, 2024 | businesswire.combluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)June 29, 2024 | americanbankingnews.combluebird bio (NASDAQ:BLUE) Stock Price Crosses Below Two Hundred Day Moving Average of $1.23July 7, 2024 | Digital Mavericks Media (Ad)1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.June 27, 2024 | globenewswire.comBLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 17, 2024 | investorplace.com7 Breakthrough Biotech Stocks for a Shot of Portfolio AdrenalineJune 2, 2024 | prnewswire.com2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a PartnerMay 29, 2024 | reuters.comBluebird bio appoints new CFO to oversee financial restatementsMay 29, 2024 | markets.businessinsider.comBluebird Bio Appoints Sterling As CFOJuly 7, 2024 | Digital Mavericks Media (Ad)1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.May 29, 2024 | businesswire.combluebird bio Appoints O. James Sterling as Chief Financial OfficerMay 27, 2024 | stockhouse.comDEADLINE TOMORROW: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the FirmMay 25, 2024 | theglobeandmail.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUEMay 25, 2024 | finance.yahoo.comBLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?May 24, 2024 | tmcnet.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)May 24, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)May 23, 2024 | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit - BLUEMay 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUEMay 22, 2024 | prnewswire.comBLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud LawsuitSee More Headlines Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today7/06/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BLUE CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees323Year FoundedN/APrice Target and Rating Average Stock Price Target$5.46 High Stock Price Target$13.00 Low Stock Price Target$1.02 Potential Upside/Downside+491.6%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$3.60 million Price / Sales28.04 Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book0.39Miscellaneous Outstanding Shares109,340,000Free Float107,040,000Market Cap$100.95 million OptionableOptionable Beta0.81 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Andrew Obenshain (Age 50)President, CEO & Director Comp: $1.04MMr. Thomas J. Klima (Age 52)Chief Commercial Officer & COO Comp: $654.97kMr. Richard A. Colvin M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $696.24kMr. Christopher Krawtschuk CPA (Age 50)CFO, Principal Accounting Officer & Treasurer Mr. Joseph D. Vittiglio Esq. (Age 52)J.D., Chief Legal & Business Officer and Secretary Jess RowlandsHead of Corporate CommunicationsMs. Andrea WaltonChief People OfficerMr. Kasra KasraianSenior Vice President of Technical Development & OperationsMr. Scott ShoemakerSenior Vice President of QualityMs. Sarah AlspachSenior Vice President of External AffairsMore ExecutivesKey CompetitorsAlloVirNASDAQ:ALVRSangamo TherapeuticsNASDAQ:SGMOTaysha Gene TherapiesNASDAQ:TSHAEditas MedicineNASDAQ:EDITFate TherapeuticsNASDAQ:FATEView All CompetitorsInsiders & InstitutionsBayesian Capital Management LPBought 40,443 shares on 5/16/2024Ownership: 0.037%Price T Rowe Associates Inc. MDBought 29,113 shares on 5/15/2024Ownership: 0.050%American International Group Inc.Bought 41,177 shares on 5/14/2024Ownership: 0.086%Vanguard Group Inc.Bought 1,723,081 shares on 5/10/2024Ownership: 9.602%SG Americas Securities LLCBought 65,710 shares on 5/7/2024Ownership: 0.073%View All Insider TransactionsView All Institutional Transactions BLUE Stock Analysis - Frequently Asked Questions How have BLUE shares performed this year? bluebird bio's stock was trading at $1.38 on January 1st, 2024. Since then, BLUE shares have decreased by 33.1% and is now trading at $0.9233. View the best growth stocks for 2024 here. How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) released its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.03. The business's quarterly revenue was up 17364.8% compared to the same quarter last year. What is Nick Leschly's approval rating as bluebird bio's CEO? 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees. How do I buy shares of bluebird bio? Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY). This page (NASDAQ:BLUE) was last updated on 7/7/2024 by MarketBeat.com Staff From Our PartnersWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on...Paradigm Press | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
